Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM for VEGFR2 and 2 nM for PDGFRβ. It inhibits autophosphorylation and RNase activation of Ire1α and selectively targets FLK1, PDGFRβ, and FLT3. Sunitinib reduces VEGF- and FGF-induced cell proliferation and tumor growth in xenograft models. Reagent grade, for research purpose.
Usually ships within 24 hours.